Remove Labelling Remove Pharmaceutical Companies Remove White Paper
article thumbnail

Why security-first design is the fix to stalling AI pilot tools

pharmaphorum

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

The EU joint HTA procedure: a gate or barrier for access?

Pharmaceutical Technology

As pharmaceutical companies launch their products across European countries, the joint procedure is intended to reduce the duplication of submissions with different evidence requirements and procedural times required at a country level, and thus streamline workflows and reduce administrative burden.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nine for 2021: Addressing the pandemic legacy

pharmaphorum

Not so China, and especially not so the lead five European countries – on average European pharmaceutical companies saw a loss of 30% of the interactive time they previously had with healthcare professionals in 2020. Whatever the challenges, the pharmaceutical industry enters 2021 with a new sense of purpose. Pharma pivots East.

article thumbnail

Dawn of a new indication: how to study drugs for aging 

Pharmaceutical Technology

Based on preclinical research for their impact on aging, well-known drugs like metformin and rapamycin are already being considered for off-label usage, due to their accepted safety profile and cost-effectiveness. Bellantuono worries that labeling aging as a disease indication could be “agist” and would have social implications.

Labelling 145
article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

Most drugs used here are prescribed off-label, and experts say pharmaceutical companies remain hesitant to conduct clinical trials studying gender-affirming care. One of the reasons why organisations, including pharma companies, do not enter this debate is because these drugs are used off label, says Horowicz.

Labelling 144
article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Moderna shines spotlight on new flu vaccine data

pharmaphorum

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)